Immunogenicity of Current and New Therapies for Hemophilia A
Anti-drug antibody (ADA) development is a significant complication in the treatment of several conditions. For decades, the mainstay of hemophilia A treatment was the replacement of deficient coagulation factor VIII (FVIII) to restore hemostasis, control, and prevent bleeding events. Recently, new p...
Tallennettuna:
| Päätekijät: | , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI AG
2022-07-01
|
| Sarja: | Pharmaceuticals |
| Aiheet: | |
| Linkit: | https://www.mdpi.com/1424-8247/15/8/911 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|